GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zynerba Pharmaceuticals Inc (NAS:ZYNE) » Definitions » Other Current Assets

Zynerba Pharmaceuticals (Zynerba Pharmaceuticals) Other Current Assets : $2.02 Mil (As of Jun. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Zynerba Pharmaceuticals Other Current Assets?

Zynerba Pharmaceuticals's other current assets for the quarter that ended in Jun. 2023 was $2.02 Mil.

Zynerba Pharmaceuticals's quarterly other current assets declined from Dec. 2022 ($2.91 Mil) to Mar. 2023 ($2.00 Mil) but then increased from Mar. 2023 ($2.00 Mil) to Jun. 2023 ($2.02Mil).

Zynerba Pharmaceuticals's annual other current assets increased from Dec. 2020 ($2.78 Mil) to Dec. 2021 ($2.83 Mil) increased from Dec. 2021 ($2.83 Mil) to Dec. 2022 ($2.91 Mil).


Zynerba Pharmaceuticals Other Current Assets Historical Data

The historical data trend for Zynerba Pharmaceuticals's Other Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zynerba Pharmaceuticals Other Current Assets Chart

Zynerba Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Other Current Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.75 2.38 2.78 2.83 2.91

Zynerba Pharmaceuticals Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Other Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.71 3.49 2.91 2.00 2.02

Zynerba Pharmaceuticals Other Current Assets Calculation

Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:


Cash
Trade Receivables
Inventory

The assets grouped under other current assets are most commonly:


Prepaid Expenses
Tax Assets
Non-Trade Receivables
Other (too numerous to list)

Some companies can and do choose to report each of these items separately.

Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.

Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.

Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.

Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.

There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.

At most companies, other current assets are a small and unimportant part of the total balance sheet.


Zynerba Pharmaceuticals Other Current Assets Related Terms

Thank you for viewing the detailed overview of Zynerba Pharmaceuticals's Other Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Zynerba Pharmaceuticals (Zynerba Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
80 West Lancaster Avenue, Suite 300, Devon, PA, USA, 19333
Zynerba Pharmaceuticals Inc is a pharmaceutical company that is focused on developing and commercializing proprietary next-generation synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product pipeline consists of Zygel which is a pharmaceutically-produced CBD, a non-euphoric cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system.
Executives
Kenneth T Jones officer: See Remarks C/O ZYNERBA PHARMACEUITCALS, INC., 80 W. LANCASTER AVENUE, SUITE 300, DEVON PA 19333
Brian Rosenberger officer: VP, Commercial & Business Dev. C/O ZYNERBA PHARMACEUTICALS, INC., 80 WEST LANCASTER AVENUE, SUITE 300, DEVON PA 19333
Terri B Sebree officer: President ZYNERBA PHARMACEUTICALS, INC., 80 W. LANCASTER AVENUE, SUITE 300, DEVON PA 19333
James E Fickenscher officer: Chief Financial Officer C/O AUXILIUM PHARMACEUTICALS, INC., 640 LEE ROAD, CHESTERBROOK PA 19087
Armando Anido director, officer: Chairman & Chief Exec. Officer 80 W. LANCASTER AVENUE, SUITE 300, DEVON PA 19333
Kenneth I Moch director 68 WILLOW AVE, LARCHMONT NY 10538
Warren D Cooper director NUTRITION 21 INC, 4 MANHATTANVILLE ROAD, PURCHASE NY 10577
Pamela Stephenson director C/O ZYNERBA PHARMACEUTICALS, INC., 80 W. LANCASTER AVENUE, SUITE 300, DEVON PA 19333
John P. Butler director C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Daniel L Kisner director 2292 FARADAY AVENUE, CARLSBAD CA 92008
William J Federici director 530 HERMAN O. WEST DRIVE, EXTON PA 19341
Albert P Parker officer: Chief Legal Officer C/O ONCOCYTE CORPORATION, 1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501
Suzanne M. Hanlon officer: Sec, General Counsel & VP HR 80 W. LANCASTER AVENUE, SUITE 300, DEVON PA 19333
Michael Rapp 10 percent owner 712 FIFTH AVENUE, 49TH FLOOR, NEW YORK NY 10019
Thomas L Harrison director

Zynerba Pharmaceuticals (Zynerba Pharmaceuticals) Headlines

From GuruFocus